m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03086)
Name
Vitamin B3
Synonyms
Niacin (TN); Niacinamide (TN); Nicotinamide (TN)
    Click to Show/Hide
Status
Approved
Structure
Formula
C6H5NO2
InChI
1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChIKey
PVNIIMVLHYAWGP-UHFFFAOYSA-N
PubChem CID
938
TTD Drug ID
D0N0ES
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Diacylglycerol O-acyltransferase 2 (DGAT2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Diacylglycerol O-acyltransferase 2 (DGAT2) is a therapeutic target for Vitamin B3. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Vitamin B3 through regulating the expression of Diacylglycerol O-acyltransferase 2 (DGAT2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Diacylglycerol O-acyltransferase 2 (DGAT2) is a therapeutic target for Vitamin B3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vitamin B3 through regulating the expression of Diacylglycerol O-acyltransferase 2 (DGAT2). [2], [3]
References
Ref 1 Glucose Is Involved in the Dynamic Regulation of m6A in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2019 Mar 1;104(3):665-673. doi: 10.1210/jc.2018-00619.
Ref 2 Acyltransferase inhibitors: a patent review (2010-present). Expert Opin Ther Pat. 2015 Feb;25(2):145-58. doi: 10.1517/13543776.2014.989833. Epub 2014 Dec 3.
Ref 3 METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. 2019 Oct 8;518(1):120-126. doi: 10.1016/j.bbrc.2019.08.018. Epub 2019 Aug 10.